scholarly journals FEASIBILITY OF COLLECTING UMBILICAL CORD BLOOD IN JORDAN AND THE EFFECT OF MATERNAL AND NEONATAL FACTORS ON HEMATOPOIETIC STEM CELL CONTENT

2014 ◽  
Vol 6 (1) ◽  
pp. e2014019 ◽  
Author(s):  
Ayad Ahmed Hussein ◽  
Randa M. Bawadi ◽  
Lubna H. Tahtamouni ◽  
Haydar Frangoul ◽  
Ali Z. ElKarmi
Keyword(s):  
Cell Viability ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Cell Content ◽  
Hematopoietic Stem ◽  
Cord Blood Transplant ◽  
Blood Banks ◽  
The Mean ◽  
Cord Blood Banks

Abstract Background: Cord blood transplant is an accepted treatment for many malignant and non-malignant diseases. We sought to determine the feasibility of collecting cord blood in Jordan and the effect of maternal and fetal factors on the quality of the cord blood units.Methods: A total of 124 cord blood units were collected and 75 (60%) cord blood units were included in this analysis. Cord blood volume, total nucleated cell (TNC) count, cell viability and CD34+ content were measured, and clonogenic assay was performed.Results: The mean volume of the collected units was 68.9 ml (range 40-115) with mean nucleated cell count of 6.5 x 108 (range 1-23.0). Our results showed a positive correlation between the volume of cord blood and TNC count (p=0.008), cell viability (p=0.001), CD34+ content (p=0.034) and the length of the umbilical cord (p=0.011). In addition, our results showed an inverse relation between the Colony Forming Unit-Granulocyte Macrophage (CFU-GM) concentration and the gestation duration (p=0.038).Conclusion: We conclude that it is feasible to collect cord blood units in Jordan with excellent TNC and CD34+ cell content. The volume of cord blood collected was associated with higher TNC count and CD34+ count. Efforts toward establishing public cord blood banks in our area are warranted.

scholarly journals UMBILICAL CORD BLOOD BANKING IN THE WORLDWIDE HEMATOPOIETIC STEM CELL TRANSPLANTATION SYSTEM: PERSPECTIVES FOR UKRAINE

2017 ◽  
Vol 39 (3) ◽  
pp. 164-170 ◽  
Author(s):  
T O Kalynychenko
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Hematopoietic Stem ◽  
Blood Banks ◽  
Cord Blood Banks

Significant progress in the promotion of procedural technologies associated with the transplantation of hematopoietic stem cells caused a rapid increase in activity. The exchange of hematopoietic stem cells for unrelated donor transplantations is now much easier due to the relevant international professional structures and organizations established to support cooperation and standard setting, as well as rules for the functioning of both national donor registries and cord blood banks. These processes are increasing every year and are contributing to the outpacing rates of development in this area. Products within their country should be regulated by the competent government authorities. This study analyzes the work of international and national levels of support for transplantation activity in the field of unrelated hematopoietic stem cell transplantation, the standardization order of technologies, as well as data that justify the need to create a network of donated umbilical cord blood banks in Ukraine as a factor in the development of allogeneic transplantation. This will promote the accessibility of international standards for the treatment of serious diseases for Ukrainian citizens.

scholarly journals A Review of Factors Influencing the Banking of Collected Umbilical Cord Blood Units

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
David Allan ◽  
Tanya Petraszko ◽  
Heidi Elmoazzen ◽  
Susan Smith
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Hematopoietic Stem ◽  
Building Inventory ◽  
Blood Banks ◽  
Cord Blood Unit ◽  
Blood Stem Cells ◽  
Alternative Sources ◽  
Cord Blood Banks

Umbilical cord blood banking efforts have increased dramatically in the past two decades in response to increasing demand for alternative sources of blood stem cells to support patients requiring hematopoietic stem cell transplantation. Transplant centres have accumulated increasing expertise in their understanding of umbilical cord blood characteristics that are associated with improved outcome following transplantation. These characteristics and factors can assist transplant centres in selecting cord blood units from the worldwide inventory of banked units. Umbilical cord blood banks, therefore, need to remain agile in adjusting the inventory of the banks to address shifts or changes in the needs of transplant centres. Public umbilical cord blood banks face the challenge of building inventory while managing limited resources and are faced with decisions regarding which units can be stored and which units that have been collected should be discarded or used for other endeavours such as research. To this end, we sought to review parameters influencing the decision to bank a collected cord blood unit. In this paper, we will address parameters associated with graft potency and address other factors that guide the decision to bank collected units.

Obstetrical and neonatal factors associated with optimal public banking of umbilical cord blood in the context of delayed cord clamping

2019 ◽  
Vol 42 (3) ◽  
pp. E56-E63 ◽  
Author(s):  
Anna Munro ◽  
Daniel J. Corsi ◽  
Lisa Martin ◽  
Michael Halpenny ◽  
Nicholas Dibdin ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Delayed Cord Clamping ◽  
Factors Associated ◽  
Cell Counts ◽  
Cord Clamping ◽  
Newborn Weight ◽  
Cord Blood Banks

Purpose: To assess the association of specific newborn and maternal factors with indicators of increased blood-forming capacity in umbilical cord blood to inform strategic collection strategies that could augment the quality of units in public cord blood banks. Methods: Data regarding 268 consecutive cord blood units (CBUs) banked by Canadian Blood Services were analyzed. Multivariate analysis was performed to identify factors associated with markers of hematopoietic potency and likelihood of utilization. Results: Delayed clamping of the cord beyond 60 s was associated with reduced volume collected. Any delay in clamping of the cord was associated with reduced total nucleated cell counts. Newborn weight >4,000 g was also associated with greater blood volume in the collection but not with other measures of hematopoietic potency. Cord blood acidosis at birth (pH

scholarly journals High Integrity and Fidelity of Long-Term Cryopreserved Umbilical Cord Blood for Transplantation

2021 ◽  
Vol 10 (2) ◽  
pp. 293
Author(s):  
Gee-Hye Kim ◽  
Jihye Kwak ◽  
Sung Hee Kim ◽  
Hee Jung Kim ◽  
Hye Kyung Hong ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Clinical Applications ◽  
Hematopoietic Stem ◽  
Cd34 Cells ◽  
Hsc Transplantation

Umbilical cord blood (UCB) is used as a source of donor cells for hematopoietic stem cell (HSC) transplantation. The success of transplantation is dependent on the quality of cord blood (CB) units for maximizing the chance of engraftment. Improved outcomes following transplantation are associated with certain factors of cryopreserved CB units: total volume and total nucleated cell (TNC) count, mononuclear cell (MNC) count, and CD34+ cell count. The role of the storage period of CB units in determining the viability and counts of cells is less clear and is related to the quality of cryopreserved CB units. Herein, we demonstrate the recovery of viable TNCs and CD34+ cells, as well as the MNC viability in 20-year-old cryopreserved CB units in a CB bank (MEDIPOST Co., Ltd., Seongnam-si, Gyeonggi-do, Korea). In addition, cell populations in CB units were evaluated for future clinical applications. The stable recovery rate of the viability of cryopreserved CB that had been stored for up to 20 years suggested the possibility of uses of the long-term cryopreservation of CB units. Similar relationships were observed in the recovery of TNCs and CD34+ cells in units of cryopreserved and fresh CB. The high-viability recovery of long-term cryopreserved CB suggests that successful hematopoietic stem cell (HSC) transplantation and other clinical applications, which are suitable for treating incurable diseases, may be performed regardless of long-term storage.

Outcome Comparisons between Two Cord Blood Banks on Different Continents Using Identical Procedures.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5230-5230
Author(s):  
Allen Lin ◽  
Steven Yang ◽  
Brian Wang ◽  
Peggy Tseng ◽  
Tina Wu ◽  
...  
Keyword(s):  
Cord Blood ◽  
Pediatric Patients ◽  
Benign Diseases ◽  
Blood Banks ◽  
Standard Operating ◽  
The Usa ◽  
Quality Programs ◽  
Recipient Age ◽  
Cord Blood Banks

Abstract Theoretically, cord blood (CB) banked using identical procedures by different banks should yield similar outcome if standard operating procedures (SOP) and quality programs are followed rigorously. To compare and validate the quality of the CB products, we studied whether all CB with available engraftment and/or survival transplant data from two banks, one in the USA and one in Taiwan, banked using virtually identical procedures, yielded similar transplantation outcome. Unadjusted engraftment of ANC500 were 91±3% for US (n=144) and 79±6% for Taiwan (n=49), while 1-year overall survival (OS) were 56±4% for US (n=153) vs. 68±7% for Taiwan (n=50). A number of obvious differences in transplants for the two banks were identified, for example, CB Transplants from the Taiwan CB bank (CBB) had more patients with benign diseases versus US (54% vs. 22%), which also influenced the proportion of pediatric patients and cell dose. Moreover, the Taiwan CBB had most units transplanted outside of the USA, whereas the USA CBB shipped most of its products within the USA. Another difference was that a higher proportion of CB were washed post-thaw for the USA CBB because USA transplant centers were more likely to practice post-thaw washing. We also analyzed the benign and malignant groups separately. For malignant patients, unadjusted engraftment of ANC500 were 92±3% for USA (n=114) and 73±10% for Taiwan (n=22), while 1-year OS were 50±5% for USA (n=120) vs. 40±11% for Taiwan (n=23). For benign indications, unadjusted engraftment of ANC500 were 89±6% for USA (n=30) and 85±7% for Taiwan (n=27), while 1-year OS were 66±9% for USA (n=33) vs. 92±5% for Taiwan (n=27). To adjust for some of these differences, a multivariate analysis was performed adjusting for malignancy, TNC dose, CD34+ dose, #HLA matches, recipient age, recipient sex, and washed status of CBU. Collectively, these data suggest that most of the apparent differences in outcome between the two banks may be explained by factors such as % malignant indications, and use of post-thaw wash. Overall, after adjustment for the differences between transplants using CB from the two banks, outcomes were quite similar, suggesting that if SOPs and quality programs were followed rigorously, results can be reproducible for CBB at disparate locations.

Mixed (Umbilical Cord Blood And Bone Marrow) Transplantation in Thalassaemia: An Experience from Eastern India

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4423-4423
Author(s):  
Subhasish Dey ◽  
Pinaki Gupta ◽  
Sushil Biswas ◽  
Ujjal Kanti Roy ◽  
Somnath Datta ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Eastern India ◽  
Sibling Donor ◽  
Cord Blood Transplant ◽  
Matched Sibling ◽  
The Mean ◽  
Stage 1

Abstract Background: Bone marrow transplant is often the preferred method of treatment for a variety of blood disorders including leukaemias, aplastic anaemia, inborn errors of metabolism and certain haemoglobinopathies (thalassaemia, sickle cell disease). Recently, several investigations have shown that cord blood is a rich source of pluripotent stem cells and it can be used effectively in place of BMT. Cord blood transplantation as a therapeutic option is a recent phenomenon in India. To date umbilical cord blood has been used in sibling and other related donors in a few centers in India. Cord blood transplant can also be used in case of a large number of patients for whom no acceptable family donor is available. The aim of our study is to see the effectiveness of umbilical cord blood as a source of stem cell transplant. MATERIAL AND METHODS: We recruited 5 patients for the sibling CBT, from July 2002 – June 2008, at our institute, which is a tertiary level cancer research institute in eastern India. The patients were properly screened for Lucarelli staging and HLA matching prior to the procedure. Out of the 5 cases 3 were fully HLA matched and 2 were mismatched. Three (3) children were in Lucarelli stage 1 and 2 were in stage 1. The sibling CBT was done at a median age of 4.5 yrs (range 3 – 12 yrs). In all the cases, cord blood was obtained shortly after the birth of the donor child, employing the closed system of collection. About 100 – 120 ml of blood was collected in each case. The blood obtained was tested for several infectious diseases including HIV and hepatitis. The blood was then sent to the appropriate laboratory for storage where it was cryopreserved at −80°C and then stored in liquid nitrogen (− 192°C) for future use. The mean no of nucleated cells infused were 2.8 × 107/kg (Range:1.2 – 7.2 × 107/kg)and the mean number of CD4+ cells infused were 3.2 × 106/kg (Range: 2.2 – 7.8 × 106/kg). The infused CFU-GM for our cases were 6 ×104/kg (4.1 – 9.2 ×104/kg). RESULTS: The median number of days to achieve engraftment was 13 days (range 9 – 13 days) for neutrophil, 33 days(range 24 – 48 days) for platelets and 80 days (33 – 148 days) for the red blood cells. All 3 patients who received HLA identical cord blood transplant engrafted, but rejection of the graft was seen in 2 patients later on at day + 180 and day + 250. Two patients who received 4/6 and 5/6 mismatched cord blood only had a partial engraftment. Out of the 3 pts who received HLA identical transplants 1 developed Gr 1 AcuteGVHD and no GVHD was seen the 2 patients who received HLA non identical CBT. Complete engraftment was seen in 2 HLA matched patients with a second transplant with the bone marrow of the same sibling. With a median follow up of 3.6 years (3 months – 6 years) all the patients are surviving – 3 being disease free(transfusion independent),2 with infrequent transfusion. CONCLUSION: In conclusion, it appears that umbilical cord blood transplant appears to be a viable option in terms of providing a cure for thalassaemia major and other haemoglobinopathies, provided it is combined with bone marrow of a matched sibling donor. In the future, we are intending to perform a mixed transplant (stored umbilical cord blood and bone marrow) if a HLA matched sibling donor is available. If no matched donor is available we will consider mismatched related or unrelated cord blood transplant.

scholarly journals The law and problematic marketing by private umbilical cord blood banks

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Blake Murdoch ◽  
Alessandro R Marcon ◽  
Timothy Caulfield
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Blood Banks ◽  
The Law ◽  
Cord Blood Banks

Transplantation perspectives in umbilical cord blood banks

2008 ◽  
Vol 38 (3) ◽  
pp. 193-197 ◽  
Author(s):  
Isidro Prat ◽  
Carmen Hernández-Lamas ◽  
Macarena Ortiz ◽  
Francisco Sánchez-Gordo ◽  
Isabel Vidales ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Blood Banks ◽  
Cord Blood Banks
Sign in / Sign up

Export Citation Format

Share Document